Please login to the form below

Not currently logged in
Email:
Password:

gouty arthritis

This page shows the latest gouty arthritis news and features for those working in and with pharma, biotech and healthcare.

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales

Ilaris is an interleukin-1 beta inhibitor and has been on sale since 2009, gradually picking up approvals for a range of inflammatory diseases including juvenile-onset rheumatoid arthritis, gouty arthritis

Latest news

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.

  • Grunenthal to market MSD’s pain drug Grunenthal to market MSD’s pain drug

    The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... gouty arthritis, which is a painful inflammation of the joints.

  • Novartis gets FDA green light for new Ilaris indication Novartis gets FDA green light for new Ilaris indication

    Immunotherapeutic wins US approval for severe form of childhood arthritis. The US FDA has cleared another indication for Novartis' fast-growing immunotherapeutic Ilaris, this time giving the nod to its use ... arthritis. Efforts to get a gouty arthritis

  • Novartis' Ilaris cleared for gouty arthritis in EU Novartis' Ilaris cleared for gouty arthritis in EU

    First biologic drug approved for condition in Europe. Novartis' Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another ... The European Commission (EC) cleared llaris (canakizumab) for the

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics